DIA Patient Organization/ Advocate Track - Drug Information Association - conference notice Rare Diseases/Orphan Products Oct 11-13th Washington, Dc

Patient Organization/ Advocate Track
Patient organizations/patients are invited to attend the US Conference on Rare Diseases and Orphan Products at a reduced registration fee of $400. Please submit a registration form to +1-215-442-6199 or Carrie.Dunn@diahome.org.

World Consumer Health Congress, Washington, DC, Slides thrown away, Conference turned “un” | Ted Eytan, MD

abstract: (repost) Differences in tumor type in low-stage versus high-stage ovarian carcinomas

Int J Gynecol Pathol. 2010
Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB; Cheryl Brown (ovarian cancer survivour/deceased) Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC.
Department of Pathology, University of Calgary, Calgary AB, Canada T2N 2T9. martin.kobel@cls.ab.ca


Abstract

Although there are recognized differences in the type of ovarian carcinomas between those tumors diagnosed at low versus high stage, there is a lack of data on stage distribution of ovarian carcinomas diagnosed according to the current histopathologic criteria from large population-based cohorts. We reviewed full slide sets of 1009 cases of 2555 patients diagnosed with ovarian carcinoma that were referred to the British Columbia Cancer Agency over a 16-year period (1984 to 2000).
On the basis of the reviewed cases we extrapolated the distribution of tumor type in low-stage (I/II) and high-stage (III/IV) tumors. We then compared the frequencies with those seen in a large hospital practice.
The overall frequency of tumor types was as follows: high-grade serous-68.1%, clear-cell-12.2%, endometrioid-11.3%, mucinous-3.4%, low-grade serous-3.4%, rare types-1.6%. High-grade serous carcinomas accounted for 35.5% of stage I/II tumors and 87.7% of stage III/IV tumors.
In contrast, clear-cell (26.2% vs. 4.5%), endometrioid (26.6% vs. 2.5%), and mucinous (7.5% vs. 1.2%) carcinomas were relatively more common among the low-stage versus high-stage tumors.
This distribution was found to be very similar in 410 consecutive cases from the Washington Hospital Center. The distribution of ovarian carcinoma types differs significantly in patients with low-stage versus high-stage ovarian carcinoma when contemporary diagnostic criteria are used, with consistent results seen in 2 independent case series. These findings reflect important biological differences in the behavior of the major tumor types, with important clinical implications.

Top Cancer Doctors to speak at upcoming Power is Teal Conference - Dr's Coleman, Goff, Seiden, Armstrong (OCNA/Washington)

Power is Teal Conference
July 10 - July 13, 2010
Washington, DC
www.ovariancancer.org/conference/2010

 

 

CONFERENCE AGENDA HIGHLIGHTS:

Saturday, July 10

Ovarian Cancer 101

presented by Dr. Robert Coleman of MD Anderson Cancer Center

 

Sunday, July 11

Research Updates Part I

presented by Dr. Barbara Goff of the University of Washington, School of Medicine

How Healthcare Reform Affects this Community

presented by Tim Westmoreland, Esq., Visiting Professor, Georgetown University School of Law

 

Monday, July 12

Research Update Part II: Mello-Abrams Lectureship Accelerating Ovarian Cancer Research: Recent Victories, Current Opportunities, Future Challenges

presented by Dr. Michael Seiden, President and CEO of Fox Chase Cancer Center

Recurrence

presented by Dr. Deborah Armstrong of Johns Hopkins Kimmel Cancer Center

 

To view the full Power is Teal Conference agenda and to register, visit www.ovariancancer.org/conference/2010.

video: Karen Mason, ovarian cancer survivor and advocate, testifies on Capitol Hill – again! | Ovarian Cancer National Alliance

Marjorie Williams: 'Woman at the Washington Zoo' : NPR

Note: This article was brought to my (and others) attention. It's not about ovarian cancer but liver cancer - excellent reading with many common thoughts ?? Your views?